linjc16/ctgov huggingface dataset:
Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head Start

Study Overview
=================
Brief Summary
-----------------
The CAP Family Advancement Study (CAP FAST) is a randomized control trial of CareerAdvance®, a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.

Detailed Description
-----------------
Randomization will take place with all applicants who have agreed to the study and are selected to participate in CareerAdvance®. Two-thirds of participants will be selected for the treatment group and will be able to enroll in CareerAdvance® immediately. The other one-third of the participants will be assigned to the control group and will not be able to enroll in CareerAdvance® for two years. Those who are selected for the control group will have access to CAP Tulsa's rich array of service outside of CareerAdvance®, including high quality early childhood education. The randomization process is introduced to parents during CareerAdvance® information sessions, and consent for the randomization process is required in order to apply to CareerAdvance®.

Official Title
-----------------
Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head Start

Conditions
-----------------
Children, Parents

Intervention / Treatment
-----------------
* Behavioral: CareerAdvance®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Families whose children attend CAP Tulsa's Early Head Start and Head Start programs, and whose parents have applied to CareerAdvance®. Exclusion Criteria: Participants who have not applied to CareerAdvance®..
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CareerAdvance®<br>CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs. | Behavioral: CareerAdvance®<br>* CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.<br>|
| No Intervention: Control Standard of CAP<br>Control participants access to CAP array of service | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parent's educational achievement | Defined education course credit attainment | 16 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low income, Education, Poverty, Children, Head Start, Parents
Taste Function and Eating Habits in Polycystic Ovary Syndrome

Study Overview
=================
Brief Summary
-----------------
This study evaluates taste function and eating habits in patients with PCOS compared to healthy women and before and after oral contraceptive use.

Detailed Description
-----------------
The objective of this study is to investigate the taste function and eating habits in patients with PCOS in comparison with healthy women at baseline and after routine use of an oral contraceptive (2mg ethinylestradiol and 0.03mg dienogest) along with general lifestyle advice for three months. Patients with diagnosis of PCOS (Rotterdam criteria) will be recruited from Hacettepe University outpatient clinics. Along with clinical, hormonal and biochemical evaluation, taste function and eating habit tests will be performed at baseline both in patients and healthy volunteers. These tests will be repeated in women with PCOS after 3 months of oral contraceptive use.

Official Title
-----------------
Investigation of Taste Function and Eating Habits in Women With Polycystic Ovary Syndrome

Conditions
-----------------
Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Drug: Contraceptive


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women diagnosed with PCOS (Rotterdam criteria) who will receive oral contraceptive pill for long-term management Exclusion Criteria: Any systemic illness Any other medication use Age<18 or >35 years Pregnant or nursing Untreated hypothyroidism or hyperthyroidism Known rhinoplasty or nasal surgery Known defect in smell or taste function Being active smoker.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Polycystic ovary syndrome<br>Women with PCOS diagnosed according to Rotterdam criteria | Drug: Contraceptive<br>* Oral contraceptive pill<br>* Other names: birth control pill;|
| Healthy control<br>Healthy women without any feature of ovulatory dysfunction or androgen excess | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Taste function | Taste function assessed by use of taste strip test | Three months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eating habits | Eating habits assessed by questionnaire | Three months |
Radical Versus Conservative Surgical Treatment of Liver Hydatid Cysts

Study Overview
=================
Brief Summary
-----------------
The management of liver hydatid cysts (LHC) is controversial. Surgery remains the basic treatment, and can be divided into radical and conservative approaches. The purpose of this study was to compare the outcome of radical and conservative surgery (CS) in the treatment of LHC and to evaluate the efficiency and safety of radical surgery (RS).

Detailed Description
-----------------
The management of liver hydatid cysts (LHC) is controversial. Surgery remains the basic treatment, and can be divided into radical and conservative approaches. The purpose of this study was to compare the outcome of radical and conservative surgery (CS) in the treatment of LHC and to evaluate the efficiency and safety of radical surgery (RS). Data from all patients with LHC treated in Sahloul Hospital, between January 2000 and December 2019, were retrieved from a retrospective database. To minimize selection bias, propensity score matching (PSM) was performed, based on variables representing patient characteristics and operative risk factors. RS especially total pericystectomy had fewer postoperative complications and lower recurrence rate compared to CS. RS may be the preferred procedure for LHC if the expertise is available.

Official Title
-----------------
Radical Versus Conservative Surgical Treatment of Liver Hydatid Cysts: A Propensity Score Matching Analysis

Conditions
-----------------
Hydatid Cyst

Intervention / Treatment
-----------------
* Procedure: hydatid cyst resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age over 14 years old. Patients presenting liver hydatid cyst . Exclusion Criteria: age less than 14 years old. Patients presenting other localization of hydtic cyst , than the liver. calcified cysts. patients with incomplete medical records. patients who were lost to follow up.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: hydatid cyst resection|radical resection of hydatic cyst|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence of hydatic cyst | recurrence of hydatid cyst after surgery | 2 years |
An Observational Study of the Correlation Between miRNA in Peripheral Blood and Prognosis in Patients With ARDS

Study Overview
=================
Brief Summary
-----------------
To evaluate the correlation between the value of miRNA related to ARDS and vascular endothelial cell and ARDS severity, vascular endothelial cell damaging degree，mortality in patients with ARDS.

Detailed Description
-----------------
After consulting literature, we obtain 14 miRNAs related to ARDS and vascular endothelial cell(ARDS-VEC-miRNAs) and 2 biomarkers of scathing vascular endothelial.The ARDS-VEC-miRNAs include miR-15a-5p,miR-16-5p,miR-21-5p,miR-24-3p,miR-26a-5p,miR-27a-3p,miR-27b-3p,miR-126-3p,miR-150-5p,miR-146a-5p,miR-155-5p,miR-221-3p,miR-223-3p,miR-320a.The biomarkers of scathing vascular endothelial include vascular cell adhesion molecule-1(VCAM-1),von Willebrand factor(vWF).20 healthy controls and 60 patients diagnose as ARDS in ICU were included in this study.we blood every participants within 24 hours after enrollment and obtain the plasma.Then, we detecte ARDS-VEC-miRNAs,VCAM-1,vWF levels in plasma by real-time quantitative PCR,record the severity of the illness and survival status within 28 days of every patients.Finally,we evaluate the correlation between the value of miRNA related to ARDS and vascular endothelial cell and ARDS severity, vascular endothelial cell damaging degree，mortality in patients with ARDS.

Official Title
-----------------
An Observational Study of the Correlation Between miRNA in Peripheral Blood and Prognosis in Patients With ARDS

Conditions
-----------------
ARDS

Intervention / Treatment
-----------------
* Other: blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:(1)Admitted to ICU, ARDS patients(Berlin criteria), (2)Patients diagnosed ARDS within 24 hours, (3)Patients age between 18 years old and 85 years. Exclusion Criteria:1)Pregnant women, 2)Patients with malignant tumor, 3)Immunosuppression or immunocompromised patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ARDS<br> | Other: blood sampling<br>* sample no more than 3ml<br>|
| Healthy control<br> | Other: blood sampling<br>* sample no more than 3ml<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | 28-day |
Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

Study Overview
=================
Brief Summary
-----------------
Our study aims to evaluate the role of Dickkopf-4 as biomarkers in the treatment of gastrointestinal stromal tumor.

Detailed Description
-----------------
To identify whether Dickkopf-4 (DKK4) could be a potential biomarker for diagnosis and prognosis in patients with gastrointestinal stromal tumor (GIST). Serum was collected from 50 patients with GIST. Serological levels of DKK4 were examined by enzyme-linked immunosorbent assay (ELISA). The sensitivity and specificity was compared with modified NIH risk criteria. A 3-year follow-up was monitored to evaluate the correlation between DKK4 serum levels and relapse-free or overall survival. The expression of DKK4 in GIST tumor tissues was also evaluated using immunohistochemistry staining.

Official Title
-----------------
Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

Conditions
-----------------
Gastrointestinal Stromal Tumor

Intervention / Treatment
-----------------
* Procedure: surgery or biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary gastrointestinal stromal tumor confirmed pathologically by surgery or biopsy Age from 18 - 70 years No serious organic and mental illness; Exclusion Criteria: Pregnancy No pathologic result Suffering other malignancies at the same time.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse-free Survival |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DKK4, Gastrointestinal Stromal Tumor, Biomarker
Effects of Dry Needling in Teres Major in Patients With Shoulder Pain

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the effects of the dry needling technique in teres major muscles on pain, range of motion, strength and extensibility of the posterior part of the tissues of the shoulder in athletes with shoulder pain.

Official Title
-----------------
Effects of Dry Needling in Teres Major in Patients With Shoulder Pain

Conditions
-----------------
Shoulder Pain

Intervention / Treatment
-----------------
* Other: Dry needling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Athletes with Shoulder pain Glenohumeral internal rotation deficit Presence of active MTrP in the teres major muscle Exclusion Criteria: Previous surgery in the upper limb Previous physiotherapy treatments in the shoulder Dry needling contraindications Previous dry needling experience to mantain the blinding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DN<br> | Other: Dry needling<br>* Dry needling based on fast-in fast-out technique in the teresa major muscle<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity | the examiners assess the pain intensity using a visual analoigue scale | Baseline | 
| Pain intensity | the examiners assess the pain intensity using a visual analoigue scale | immediately after the intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Range of motion | the examiners assess the shoulder range of motion with an universal goniometer | Baseline | 
| Range of motion | the examiners assess the shoulder range of motion with an universal goniometer | immediately after the intervention | 
| Strength | the examiners assess the shoulder range of motion with a hand-held dynamometer | Baseline | 
| Strength | the examiners assess the shoulder range of motion with a hand-held dynamometer | immediately after the intervention | 
| Extensibility | the examiners assess the extensibility of the posterior part of the tissues of the shoulder using a digital inclinometer | Baseline | 
| Extensibility | the examiners assess the extensibility of the posterior part of the tissues of the shoulder using a digital inclinometer | immediately after the intervention |
Observational Study of Patients With Diabetes Using Levemir® FlexPen®

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea. The aim of this observational study is to evaluate the short term and the long term safety and efficacy of Levemir® FlexPen®. The study is planned and conducted as per requirement from Korea Food and Drug Administration (KFDA).

Official Title
-----------------
Safety and Efficacy of Insulin Detemir (Levemir® FlexPen®) in Patients With Diabetes Mellitus

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetes Mellitus Exclusion Criteria: Contra-indication based on local label
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br> | Drug: insulin detemir<br>* Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events |  | for the duration of the trial | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight |  | for the duration of the trial | 
| FBG (Fasting Blood Glucose) |  | for the duration of the trial | 
| 2hr-PPBG (2hr-Post Prandial Blood Glucose) |  | for the duration of the trial | 
| HbA1c |  | for the duration of the trial | 
| Adverse events |  | for the duration of the trial | 
| Clinical laboratory abnormality |  | for the duration of the trial |
Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.

Official Title
-----------------
Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer

Conditions
-----------------
Breast Neoplasms

Intervention / Treatment
-----------------
* Drug: aspirin
* Drug: Exemestane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Breast cancer after surgery postmenopausal Exclusion Criteria: contraindication of aspirin

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exemestane + Aspirin<br> | Drug: aspirin<br>* Aspirin 50mg po daily<br>Drug: Exemestane<br>* Exemestane 25mg po daily<br>|
| Active Comparator: Exemestane<br> | Drug: Exemestane<br>* Exemestane 25mg po daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Life |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exemestane, aspirin, quality of life
Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients

Study Overview
=================
Brief Summary
-----------------
Most high risk keratoplasties are currently performed under systemic immunosuppression. Immunosuppressants are currently either Cyclosporine A or mycophenolate mofetile, administered for around 6 months. Due to potentially severe adverse effects, new immunosuppressive exerting less side effects would be desirable. Basiliximab is a monoclonal, chimeric antibody, targeted specifically against the Interleukin-2-Rezeptor from activated T-cells. This agent is known to specifically inhibit T-cell proliferation upon intravenous application only twice following transplantation. Basiliximab has already been demonstrated effective in kidney transplantation. This investigation is a prospective, randomized clinical trial on orthotopic, high-risk penetrating keratoplasty. Basiliximab is evaluated against systemic Cyclosporine A. Primary endpoint is graft rejection. Secondary endpoint is clear graft survival.

Official Title
-----------------
Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients

Conditions
-----------------
Corneal Transplantation

Intervention / Treatment
-----------------
* Drug: Basiliximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: high risk keratoplasty Exclusion Criteria: normal risk keratoplasty
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Basiliximab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Graft rejection |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clear graft survival |  |  |